AstraZeneca PLC (AZN)vsGinkgo Bioworks Holdings (DNA)
AZN
AstraZeneca PLC
$184.74
-1.40%
HEALTHCARE · Cap: $287.11B
DNA
Ginkgo Bioworks Holdings
$9.70
+14.66%
HEALTHCARE · Cap: $551.05M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 34421% more annual revenue ($58.74B vs $170.16M). AZN leads profitability with a 17.4% profit margin vs -183.8%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
DNA
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$184.74
$29.77 discount
Margin of Safety
+33.4%
Fair Value
$14.03
Current Price
$9.70
$4.33 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -51.1% — below average capital efficiency
Revenue declined 23.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : DNA
The strongest argument for DNA centers on Price/Book.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : DNA
The primary concerns for DNA are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a value stock while DNA is a turnaround play — different risk/reward profiles.
DNA carries more volatility with a beta of 1.57 — expect wider price swings.
AZN is growing revenue faster at 4.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 29/100), backed by strong 17.4% margins. DNA offers better value entry with a 33.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Ginkgo Bioworks Holdings
HEALTHCARE · BIOTECHNOLOGY · USA
Ginkgo Bioworks Holdings (DNA) is a frontrunner in the synthetic biology industry, leveraging cutting-edge genetic engineering techniques to develop tailored bioengineered organisms for diverse applications in pharmaceuticals, agriculture, and industrial biotechnology. The company’s innovative platform enhances cellular design for manufacturing, optimizing product development and streamlining production processes. With a strong focus on solving critical global challenges, including climate change and food security, Ginkgo is well-positioned to influence multiple sectors while fostering sustainable advancements in biotechnology. As the industry evolves, Ginkgo's commitment to bio-based solutions positions it for significant growth and impact.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?